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Summary Following breast-conserving surgery for ductal carcinoma in situ (DCIS), the presence of comedo necrosis reportedly predicts for
higher rates of post-operative recurrence. To examine the role of programmed cell death (apoptosis) in the aetiology of the cell death
described as comedo necrosis, we studied 58 DCIS samples, using light microscopy, for morphological evidence of apoptotic cell death. The
percentage of apoptotic cells (apoptotic index, Al) was compared between DCIS with and without evidence of 'comedo necrosis' and related
to the immunohistochemical expression of the anti-apoptosis gene bcl-2, mitotic index (Ml), the cellular proliferation antigen Ki67, nuclear
grade and oestrogen receptor (ER) status. Al was significantly higher in DCIS samples displaying high-grade comedo necrosis than in low-
grade non-comedo samples: median Al = 1.60% (range 0.84-2.89%) and 0.45% (0.1-1.31%) respectively (P < 0.001). Increasing nuclear
grade correlated positively with Al (P< 0.001) and negatively with bcl-2expression (P= 0.003). Bcl-2 correlated negatively with Al (P= 0.019)
and strongly with ER immunoreactivity (P < 0.001). Cellular proliferation markers (Ml and Ki67 immunostaining) correlated strongly with Al
and were higher in comedo lesions and tumours of high nuclear grade (P < 0.001 in all cases). Thus, apoptosis contributes significantly to the
cell death described in ER-negative, high-grade DCIS in which a high proliferative rate is associated with a high apoptotic rate. It is likely that
dysregulation of proliferation/apoptosis control mechanisms accounts for the more malignant features typical of ER negative comedo DCIS.
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The initiation and progression of breast cancer depends upon the
survival of genetically altered epithelial cells. Cell survival is a
regulated process that depends on the balance between factors that
promote or inhibit programmed cell death. In recent years, there
has been increasing interest in the role of programmed cell death
or apoptosis in oncogenesis. Distinct from necrosis, which occurs
in response to some noxious stimuli, apoptosis is the result of a
genetically programmed sequence ofevents that allows individual
cells to die. Cells undergoing apoptotic death display characteristic
morphological features and are removed by phagocytosis in the
absence of any inflammatory response, thereby permitting cell
death without damage to adjacent cells (Schwartzman and
Cidlowski, 1993; Kerr et al, 1994). Apoptosis is believed to act as
the counterbalance to proliferation (mitosis) and is a critical factor
in tissue homeostasis (Potten, 1992). Dysregulation of the apo-
ptotic process may therefore play a crucial role in oncogenesis.
The bcl-2 proto-oncogene has emerged as an important regu-
lator of apoptosis (Hockenbery, 1990) and was first described as a
result ofchromosomal translocation seen in follicular B-cell lines;
resultant overexpression of bcl-2 protein confers resistance to
apoptotic cell death in affected lymphocytes (Weiss et al, 1987).
Subsequently, the bcl-2 protein product has been described in a
variety of fetal and adult epithelial tissue. In particular, bc1-2 has
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been demonstrated in epithelial cells where the processes ofhyper-
plasia and involution are under hormonal or growth factor regula-
tion (e.g. breast), in differentiating epithelium possessing
long-lived stem cells (e.g. intestine) and in fully differentiated
long-lived non-cycling cells (e.g. neurones) (Hockenbery et al,
1991; Merrit et al, 1995). Whereas the patterns ofbcl-2 expression
have been extensively studied in normal breast epithelium and in
invasive breast cancer, there has been little examination of bcl-2
expression and apoptosis within in situ ductal carcinoma (DCIS)
ofthe breast (Siziopikou et al, 1996).
DCIS has been increasingly diagnosed since the adoption of
high-quality screening mammography and now accounts for up to
30% of screen-detected malignancies (Ernster et al, 1996). Despite
the large increase in women diagnosed with DCIS, treatment
remains controversial. Although mastectomy offers cure rates of
up to 98%, it is overtreatment for the 60% of women with DCIS
that will not progress to invasive cancer. However, after localized
breast-conserving surgery, 30% of women will have recurrent
lesions within 15 years and half of these will be invasive cancer,
and therefore potentially incurable (Page et al, 1982). The only
available prospective randomized clinical trial examining adjuvant
therapy for women with DCIS has recommended post-operative
radiotherapy for all patients treated by breast-preserving surgery
(Fisher et al, 1995). This policy has since been questioned as no
subset analysis was performed that may have separated a subgroup
ofpatients in whom radiotherapy was unnecessary from those who
had an increased risk of local relapse (Page and Lagios, 1995).
One feature ofDCIS reported by Fisher et al (1995) to be indepen-
dently predictive of higher recurrence rates and progression to
invasive breast cancer was the presence of so-called comedo
'necrosis,' and this finding has also been noted by other authors
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(Lagios, 1990; Solin et al, 1993; Bellamy et al, 1993).
Consequently, comedo necrosis has become an important compo-
nent of a number of proposed classifications for DCIS. In a recent
critical appraisal of six modern DCIS classifications it emerged
that, in the evaluation of each DCIS sample, disagreements
between histopathologists were least common in the assessment of
necrosis (Douglas-Jones et al, 1996).
However, the nature of the spontaneous cell death leading to the
histopathological appearance of 'comedo-type necrosis' is uncertain,
but recent evidence implicates apoptosis as an important component
(Bodis et al, 1996). Recognition of apoptosis in DCIS and an under-
standing of the hormonal regulation of this physiological process
may allow potential therapeutic options to be developed.
The aim of this study was, therefore, to evaluate the presence
and distribution of apoptosis in ductal carcinoma in situ in an
attempt to investigate the role of apoptosis in the development of
invasive cancer from in situ lesions.
MATERIALS AND METHODS
Clinical data
Fifty-eight samples of archival formalin-fixed paraffin-embedded
specimens of breast DCIS were randomly obtained from the
Pathology Department at the University Hospital of South
Manchester. All patients had purely in situ ductal carcinoma with no
invasive component and had undergone breast surgery between 1976
and 1994, no patient had received preoperative adjuvant therapy. The
median age ofpatients was 53 years (range 26-75 years).
Histological analysis
Haematoxylin-eosin (H&E)-stained sections were examined by an
experienced breast pathologist and classified according to the archi-
tectural pattern as either comedo or non-comedo type (Page et al,
1989). Necrosis involving greater than 30% of the diameter of
affected ducts was considered to represent comedo-type necrosis
(Siziopikou et al, 1996). Samples displaying a mixture of both
comedo and non-comedo subtypes were classified as 'mixed'.
Nuclear grade of DCIS lesions was defined as grades 1-3 in
order of increasing pleomorphism (Lagios, 1990; Bellamy et al,
1993). Typically, grade 3 nuclei were large, showed irregularity in
contour and contained multiple nucleoli, whereas grade 1 nuclei
showed bland, uniform morphology. Grade 2 nuclei exhibited
intermediate characteristics.
Immunohistochemical staining
Tissue sections were deparaffinized in two 5-min changes ofxylene
and rehydrated through a series of alcohols to water. The sections
were then immersed in 10 mM citrate buffer solution (pH 6) and
antigen retrieval obtained by heating in a microwave oven (20 min
forbcl-2 antigen; 25 min for ER and Ki67 antigen). The slides were
cooled for 20 min in the citrate buffer before immersion in
phosphate buffer solution (PBS; pH 7.6). Endogenous peroxidase
activity was blocked by washing with 0.3% hydrogen peroxide in
PBS for 15 min. Immunostaining then proceeded as follows.
Ki67antigen
Following blockage of non-specific binding by incubating with
casein (0.5 ml in 100 ml of PBS) for I h at room temperature,
slides were incubated with primary antibody (polyclonal rabbit
anti-human Ki67; Dako catalogue no. A047, Dako, High
Wycombe, UK) at 1:50 dilution for 30 min at RT. A biotinylated
swine anti-rabbit secondary antibody (Dako E431) was applied
(1:400 dilution, 30 min at RT) following two washes in PBS.
ER detection
Twenty per cent normal rabbit serum (Dako X902) was used to
block non-specific binding (applied for 15 min) before overnight
incubation at 4°C with the primary antibody (1:100 dilution of
monoclonal mouse anti-human ER; Dako M7047). A biotinylated
rabbit anti-mouse immunoglobulin (Dako E413) was employed as
the secondary antibody (1:350 dilution, incubated for I h).
bcl-2 antigen
Slides were rinsed in a solution of 2% bovine serum albumin
(BSA), 1% goat serum and 0.1% Triton X-100 in Tris-buffered
saline (TBS; pH 7.4) for 45 min to prevent non-specific binding
before incubation with the primary antibody (monoclonal mouse
anti-human bcl-2; Dako M887) overnight at 4°C (1: 100 dilution in
preblock solution). Following two 5-min rinses in TBS/0.5%
Tween solution, 10% goat serum was applied for 30 min at room
temperature (RT). The secondary antibody (biotinylated goat anti-
mouse immunoglobulin; Vector Labs) was then applied within a
solution ofTBS/0.5% Tween/5% normal human serum (1:200 dilu-
tion for45 min at RT). A sample ofhuman stomach was used as the
positive control in each staining run, the lymph nodes contained
therein staining positive in the presence of anti-bcl-2 antibody.
Following incubation with the secondary antibody, a standard
three-layered streptavidin-avidin-biotin horseradish peroxidase
technique was used to highlight the signal, with diaminobenzidine
as the chromogen and haematoxylin as a light counterstain.
To obtain ER and Ki67 labelling scores for each specimen, a
minimum of 1000 malignant cells was counted per slide and the
number of positively stained nuclei calculated as a percentage
(positive cells/total no. of cells counted). Intensity of the nuclear
stain was variable, but this was not assessed separately; any
nucleus with detectable staining above background levels (nega-
tive control without primary antibody) were counted as positive.
Slides scored for ER were grouped depending upon the percentage
of cells labelled (group 1 = < 5%, group 2 = 5-25%, group 3 =
26-50%, group 4 = > 50% cells stained). Subdivision of the
samples into groups depending on ER labelling score allowed
examination of correlation between degree of ER immunoreac-
tivity and other variables. A score of > 5% was taken to represent
ER positivity.
Bcl-2 staining was cytoplasmic. Semiquantitative evaluation of
bcl-2 expression was performed by assessing the percentage of
malignant cells on each slide displaying bcl-2 staining (Sierra et al,
1995). Samples were then categorized into four groups (group 1,
0% of cells exhibiting bcl-2 immunoreactivity; group 2, < 33%;
group 3, 34-66%; group 4, > 66% ofcells stained).
Assessment of apoptotic and mitotic indices
H&E-stained sections oftissue samples were examined using light
microscopy for morphological evidence of apoptosis and mitosis.
The criteria used to identify apoptotic cells are well recognized
(Schwartzman and Cidlowski, 1993; Carson and Ribiero, 1993;
Kerr et al, 1994; Potten, 1996) and include condensation of chro-
matin initially at the margins of the nucleus, condensation of the
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Table 1 The relationship between histological architecture, nuclear grade, bcl-2 immunoreactivity and ER status of 58 DCIS specimens. Bcl-2 staining was
considered positive (bcl-2 +ve) when any evidence of cytoplasmic immunoreactivity was seen. ER status was considered positive (ER +ve) when > 5% of
counted malignant epithelial cells showed nuclear immunostaining
Comedo Mixed Non-comedo Grade Grade Grade bcl-2 bcl-2
(n = 10) (n = 26) (n = 22) 1 2 3 +ve -ve
Grade 1 (n= 8) (14%) 0 0 8
Grade 2 (n= 21) (36%) 2 11 8
Grade 3 (n=29) (50%) 8 15 6
bcl-2 +ve (n= 32) (55%) 3 13 16 7 13 12
bcl-2-ve (n=26) (45%) 7 13 6 1 8 17
ER +ve (n = 39) (67%) 4 18 17 7 17 15 28 11









Figure 1 A boxplot displaying the apoptotic indices (Al) for the differing
subtypes of DCIS. The upper and lower margins of each box represent the
interquartile range, the line within each box the median and the whiskers
above and below the boxes the range of values for each subtype. 'Mixed'
represents DCIS samples displaying both comedo and non-comedo patterns
and Al scores for both components are presented (mc, comedo; m-nc, non-
comedo). No differences in Al are observed between the comedo and non-
comedo components of 'mixed' DCIS and samples containing purely one
type of DCIS. Comedo DCIS is seen to have a higher Al than non-comedo
DCIS in all cases (P < 0.001)
cytoplasm (chromophilia), detachment from surrounding cells
indicated by the appearance of a characteristic halo around the
dying cell and cytoplasmic budding to form membrane-bound
fragments (apoptotic bodies). Mitosis was identified by the loss of
the nuclear membrane and the condensation of nuclear chromatin
and included all stages from late prophase to late anaphase.
To obtain the apoptotic index (Al) and mitotic index (MI), at
least four fields containing DCIS were selected at low power and
cells counted using a x 40 Planapo oil lens and a Zeiss microscope.
A minimum of 1000 malignant epithelial cells were counted per
sample and the number of cells displaying apoptotic or mitotic
morphology expressed as a percentage of the total number
counted. Intraobserver and interobserver variability for both Al
and MI was low [r = 0.95 (P < 0.001) and r = 0.88 (P < 0.001)
respectively.
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS,
Chicago, IL, USA) by the CRC Department of Computing and
Biomathematics at the Paterson Institute for Cancer Research.
Non-parametric tests (Mann-Whitney or Kruskal-Wallis tests as
appropriate) were used to compare median values between groups
of variables and Spearman's rank correlation coefficient to
examine the degree of correlation between variables. A multi-
variate analysis was performed using a general linear model to
examine the relative contributions of four categorical variables
(histological subtype, ER positivity, nuclear grade and bcl-2
immunoreactivity) to Al values. A significance level of 5% was
used throughout.
RESULTS
Ten (17%) of the 58 specimens were pure comedo subtype, 22
(38%) were non-comedo and 26 (45%) displayed mixed comedo
and non-comedo architecture. Each ofthe ten comedo DCIS cases
exhibited areas ofnecrosis that occupied > 30% ofinvolved ducts;
non-comedo cases also exhibited some evidence of necrosis but
this was minor in comparison with the comedo DCIS and in no
case did necrosis approach 30% ofductal diameter. Thirty-nine of
the 58 samples (67%) displayed ER immunoreactivity in . 5% of
cells and were therefore considered ER positive. Bcl-2 staining
was noted in 32 (55%) specimens. Eight (14%), 21 (36%) and 29
(50%) ofthe cases were nuclear grade 1, 2 and 3 respectively. The
relationships between histological architecture, nuclear grade,
bcl-2 immunoreactivity and ER status are shown in Table 1.
Apoptotic and proliferative indices
The apoptotic index was significantly higher in comedo DCIS
[median = 1.60% (range 0.84-2.89%)] than in mixed and non-
comedo subtypes [median = 1.11% (0.32-2.07%) and median =
0.45% (0.1-1.31%) respectively]; P < 0.001 in both cases, Figure
1. This high apoptotic rate for comedo DCIS was maintained when
the Al for the comedo component of the 26 'mixed' samples
(exhibiting both comedo and non-comedo architecture) was
assessed independently ofthe non-comedo component ofthe same
samples. In these mixed samples, the median Al for the comedo
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Table 2 The relationship between apoptotic index (Al) and proliferative indices [mitotic index (Ml) and Ki67 labelling index] and histological subtype, ER status
and nuclear grade in 58 samples of DCIS. Significance values for differences between groups are given below
Variable Number Median AI% (range) Median Ml% (range) Median Ki67% (range)
Histological subtype
Comedo 10 1.60 (0.84-2.89) 0.67 (0.29-1.24) 12.52 (4.32-21.02)
Mixed 26 1.11 (0.32-2.07) 0.25 (0-0.63) 9.72 (0.53-20.15)
Non-comedo 22 0.45 (0.10-1.31)a 0.09 (0-1.31)a 4.03 (0-15.41)a
ER status
< 5% of cells stained 19 1.48 (0.3-3.00) 0.3 (0-0.9) 11.98 (2.98-21.02)
2 5% of cells stained 39 0.79 (0.29-1.60)b 0.19 (0-1.24)c 6.79 (0-18.27)b
Nuclear grade
Grade 1 8 0.35 (0.3-0.58) 0 (0-0.39) 2.92 (0-4.61)
Grade 2 21 0.88 (0.1-1.59) 0.15 (0-0.84) 5.24 (0.53-16.8)
Grade 3 29 1.48 (0.29-3.00)b 0.35 (0.09-1.24)a 11.65 (0.8-21.02)a






















Figure 2 A boxplot demonstrating the relationship between apoptotic index
(Al%), bcl-2 immunoreactivity score and nuclear grade in DCIS. The upper
and lower margins of each box represent the interquartile range, the line
within each box the median and the whiskers above and below the boxes
the ranges for each grade. Al is seen to rise with increasing nuclear grade
(P = 0.001). A superimposed median bcl-2 immunoreactivity score (*) is
given for each nuclear grade of DCIS. An inverse relationship is seen
between the degree of bcl-2 immunoreactivity and levels of apoptosis
(r = - 0.31, P = 0.02)
component was 1.80% (range 0.7-2.79%), significantly higher
than the non-comedo component [0.78% (range 0.10-1.53%); P <
0.001] but statistically similar to the Al of the 'pure' comedo
samples (P = 0.97); Figure 1. Increasing Al correlated positively
with increasing nuclear grade (r = 0.52, P < 0.001; Figure 2)
and negatively with increasing ER immunoreactivity (r = - 0.29,
P = 0.026); Table 2.
Both markers of cell proliferation, Ki67 immunostaining and
mitotic index (MI), displayed a strong mutual positive correlation
(r = 0.50, P < 0.001) and both were positively associated with Al
(r = 0.60 and 0.58 respectively, P < 0.001). Figure 3 displays the
relationship between Ki67 and Al. Proliferative indices were
highest in comedo subtype (Table 3) and tumours of high nuclear
grade. Increasing ER immunoreactivity correlated with decreasing

























Figure 3 A scatter plot showing the strong positive correlation between
apoptotic index (Al%) and the labelling index for the Ki67 antigen, a marker
of cell proliferation
Bcl-2 immunostaining
Bcl-2 immunostaining displayed a negative correlation with Al
(r = - 0.31, P = 0.02; Figure 2) and with increasing nuclear grade
(r = - 0.38, P = 0.003; Figure 2). A strong correlation with
hormone receptor status was noted with bcl-2 immunoreactivity
increasing with rising ER status (r = 0.62, P < 0.001). Comedo
DCIS displayed the lowest bcl-2 immunoreactivity and non-
comedo the highest, with mixed type DCIS showing intermediate
staining (median bcl-2 immunostaining scores 0, 3 and 1
respectively; P = 0.016). There was a negative correlation with
markers ofcellular proliferation (MI, r = - 0.33, P = 0.013; Ki67,
r=-0.44, P=0.001).
Multivariate analysis
The two most significant contributors to the Al were the presence
of comedo 'necrosis' (P<0.001) and negative ER status (P =
0.006). If these two variables were used then nuclear grade and
bcl-2 immunoreactivity did not add any further predictive value to
the linear model.
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DISCUSSION
Significant apoptosis occurs in ductal carcinoma in situ of the
breast and its extent is closely correlated with histological and
biological parameters. We have used light microscopy to identify
cells undergoing apoptosis and mitosis. Apoptosis may be recog-
nized in properly fixed, well-sectioned, H&E-stained sections by
the morphological features mentioned above. In addition, apo-
ptosis affects scattered individual cells, that are then removed by
phagocytosis by neighbouring cells, whereas necrosis involves
groups of adjoining cells and invokes a local inflammatory
response. Here, dying cells were individually scattered throughout
the malignant DCIS epithelium in a manner similar to that
described in studies of apoptosis within invasive breast cancer
(Lipponen et al, 1994) and other epithelial malignancies (for
review see Schwartzman and Cidlowski, 1993). Whereas it is
accepted that morphological assessment of apoptosis may only
detect those cells in the end stages of the apoptotic process, other
methods of detection of apoptosis, e.g. a terminal transferase-
based staining assay (or its variant in situ end labelling), have yet
to be shown to be as reproducible as determination of the morpho-
logical apoptotic index. Furthermore, the ability of such end-
labelling techniques to distinguish between DNA breaks induced
by apoptosis or necrosis is not completely established (discussed
fully in Potten, 1996). In our hands in situ end-labelling has a false
positive rate of up to 1.6% and a false-negative rate of up to 35%,
and we consider morphological change to be the reference
standard in the evaluation of apoptotic cell counts (Potten, 1996).
Apoptosis was notably higher in comedo type DCIS than in
non-comedo DCIS and this held true when the comedo component
of samples displaying both subtypes ('mixed' DCIS) was
compared with the non-comedo component (Figure 1). Our data
add to emerging evidence (Bodis et al, 1996; Siziopikou et al,
1996) that apoptosis is a major contributory factor to the sponta-
neous cell death (currently labelled intraduct necrosis) that is a
typical feature of comedo DCIS (Lagios 1990; Holland et al, 1990;
Fisher et al, 1995). Extensive intraduct necrosis is not a common
feature of non-comedo DCIS and we have found that Al is much
lower in this group of DCIS lesions.
A recent critical appraisal of six classification systems for DCIS
noted the extent of necrosis in each DCIS sample to be the factor
displaying the least interobserver variability (Douglas-Jones et al,
1996). Consequently, we have identified only two subtypes of
DCIS, comedo or non-comedo, based on the presence or absence
of 'necrosis' affecting greater than 30% of the diameter of affected
ducts (Siziopikou et al, 1996), thereby avoiding the requirement to
identify the individual subtypes of DCIS (solid, cribriform etc.) in
each sample, a classification method reported to produce the
greatest interobserver variation.
Another integral feature of modern DCIS classification systems
discussed by Douglas-Jones et al (1996) is the assessment of
nuclear pleomorphism. Increasing nuclear pleomorphism corre-
lates strongly with the comedo subtype of DCIS (Table 1).
Furthermore, we have noted Al to be closely related to the nuclear
grade of the DCIS lesions (Figure 2). Whereas Bodis et al (1996)
failed to find any evidence of apoptosis in grade 1 DCIS lesions,
we have found the median Al in nuclear grade 1 DCIS lesions to
be 0.35%, a value similar to that described in normal breast epithe-
lium taken from women undergoing a breast biopsy for fibro-
adenoma [0.33% and 0.35% by Allan et al (1992) and Potten et al
(1988) respectively]. It is unlikely that apoptosis is present.in
normal epithelium yet totally absent in malignancy (DCIS), and
our finding ofgenetically programmed cell death in grade 1 DCIS
probably represents the 'background' apoptosis seen in normal
breast tissue. Increasing nuclear grade resulted in a striking
increase in Al (median Al for grade 2 and grade 3 lesions = 0.88%
and 1.40% respectively) and is consistent with the possibility that
apoptosis in breast malignancies correlate with proliferative poten-
tial (Bodis et al, 1996; Lipponen et al, 1994).
A strong correlation between Al and known markers ofcellular
proliferation (mitotic index and Ki67 immunoreactivity) was seen,
with increasing proliferation accompanied by increasing apoptosis
(Figure 3). The close correlation between apoptosis and prolifera-
tion suggests that interactive mechanisms may be involved in the
regulation of these pathways and the c-myc and c-erbB-2 proto-
oncogenes are emerging as important components in this regula-
tory process. c-myc has the unusual property of being intimately
implicated in the two processes of cell proliferation and apoptotic
cell death (Bissonette et al, 1992; Fanidi et al, 1992). The opposing
roles of c-myc in cell growth and death require that other gene
products dictate the outcome of c-myc expression on a cell. In the
presence ofappropriate cell survival factors, c-mvc overexpression
drives cell proliferation, whereas in their absence c-myc over-
expression results in the cell advancing to apoptosis. One such
putative cell survival factor is the bcl-2 proto-oncogene, which has
been shown to block c-myc-induced apoptosis but not prolifera-
tion. Bissonnette et al (1992) showed that cells that underwent heat
shock-induced overexpression of c-myc died with features charac-
teristic of apoptosis. Transfection of the same cell types with
human bcl-2 markedly increased resistance to apoptosis. Fanidi et
al (1992) demonstrated the bcl-2 abrogation of c-mvc-induced
apoptosis but not proliferation in fibroblasts.
Overexpression of the c-erbB-2 proto-oncogene is associated
with a high proliferative drive, occurring in 75-100% of comedo
DCIS lesions but only 0-7% ofnon-comedo lesions (Van de Vijver
et al, 1988; Barnes et al, 1991). We have previously shown that
comedo DCIS is hormone independent and does not require
oestrogen to maintain its high proliferative rate (Holland et al,
1997). In the absence of hormone dependence, it is possible that
the high proliferative rate seen in high-grade ER-negative comedo
DCIS (Table 3) is driven by proto-oncogenes such as c-erbB-2.
This hypothesis is supported by in vitro studies that demonstrate
that breast epithelial cells overexpressing c-erbB-2 have signifi-
cantly higher proliferation rates and that the same cells exhibit
enhanced levels of apoptosis compared with control cells when
serum deprived (Harris et al, 1995). Also, anti-c-erbB-2 antibodies
cause inhibition ofcellular proliferation (Deshane et al, 1994) and
an increase in cell death by apoptosis (Deshane et al, 1996). These
findings may explain the positive correlation that we (Figure 3)
and others (Lipponen et al, 1994) have found between apoptosis
and cellular proliferation.
We have found an inverse relationship between bcl-2 expression
and Al (Figure 2). High Al was found in the comedo subtype, high-
grade lesions and ER-negative lesions, all ofwhich showed low bcl-
2 immunoreactivity, whereas all DCIS samples showing low Al
(non-comedo subtype, nuclear grade 1 lesions and lesions showing
marked ER immunostaining) had relatively higher bcl-2 immuno-
reactivity. A particularly strong positive association was noted
between bcl-2 and ER immunoreactivity. The relationship between
bcl-2 expression and hormone receptor status has been documented
by others in invasive breast cancer (Johnstone et al, 1994; Leek et al,
1994) and in normal breast epithelium during the menstrual cycle
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(Sabounin et al, 1994) leading to the hypothesis that bcl-2 expression
is oestrogen regulated via the ER. This hypothesis is further
strengthened by the finding that apoptosis varies through the
menstrual cycle (Ferguson and Anderson, 1981) peaking at the end
of the cycle at a time when bcl-2 expression has been shown to be
declining (Sabourin et al, 1994); however not all investigators have
demonstrated a cyclical variation in Al (Potten et al, 1988). The
combination of bc1-2 expression and positive ER status has been
shown to predict an enhanced benefit from anti-oestrogen therapy
(Gee et al, 1994) and preoperative administration of tamoxifen
increases bcl-2 expression while decreasing the Ki67 proliferation
index (Johnstone et al, 1994). Thus, in invasive cancers, there is
considerable evidence that bcl-2 expression is hormonally regulated
and may be an important regulator ofapoptosis.
Transgenic mouse tumour models suggest that in proliferative
lesions which have a high rate of spontaneous proliferation and
apoptosis, progression to frankly malignant, aggressive, invasive
tumours occurs if apoptosis is impaired and proliferation main-
tained (Symonds et al, 1994). In addition, Yin et al (1997) have
shown that loss of apoptosis-promoting factors (p53 and bax
proteins) results in a dramatic acceleration of tumour growth and
that there is a direct relationship between loss of apoptosis and
rates oftumour growth. As the mean number ofapoptotic cells per
mm- of invasive breast cancer is about ten (Lipponen et al, 1994)
apoptosis may be less prevalent in invasive breast cancer than
within in situ ductal carcinoma. It is therefore possible that loss of
apoptosis pari passu with a high proliferative rate contributes to
progression from the in situ to the invasive phenotype. Additional
genetic mutations or alterations, e.g. loss of cell adhesion mole-
cules may also be critical for the development of the invasive
phenotype (Tsuda et al, 1995; Gupta et al, 1997).
In conclusion, we have identified a subset of DCIS lesions that
has a high Al and high proliferative rate. These lesions tend to be
ER negative, of high nuclear grade and display little or no bcl-2
immunostaining. It is the same subset of DCIS lesions, displaying
comedo architecture, that is associated with local recurrence or
progression to the invasive phenotype. Apoptosis contributes
substantially to the cell death seen within these in situ carcinomas.
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